JP2005506334A5 - - Google Patents

Download PDF

Info

Publication number
JP2005506334A5
JP2005506334A5 JP2003532491A JP2003532491A JP2005506334A5 JP 2005506334 A5 JP2005506334 A5 JP 2005506334A5 JP 2003532491 A JP2003532491 A JP 2003532491A JP 2003532491 A JP2003532491 A JP 2003532491A JP 2005506334 A5 JP2005506334 A5 JP 2005506334A5
Authority
JP
Japan
Prior art keywords
disease
pharmaceutical composition
composition according
conh
thiophene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003532491A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005506334A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/031902 external-priority patent/WO2003029242A1/en
Publication of JP2005506334A publication Critical patent/JP2005506334A/ja
Publication of JP2005506334A5 publication Critical patent/JP2005506334A5/ja
Pending legal-status Critical Current

Links

JP2003532491A 2001-10-04 2002-10-04 ＮＦ−κＢ阻害剤 Pending JP2005506334A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32697601P 2001-10-04 2001-10-04
PCT/US2002/031902 WO2003029242A1 (en) 2001-10-04 2002-10-04 NF-λB INHIBITORS

Publications (2)

Publication Number Publication Date
JP2005506334A JP2005506334A (ja) 2005-03-03
JP2005506334A5 true JP2005506334A5 (https=) 2006-01-05

Family

ID=23274589

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003532491A Pending JP2005506334A (ja) 2001-10-04 2002-10-04 ＮＦ−κＢ阻害剤

Country Status (7)

Country Link
US (1) US7166639B2 (https=)
EP (1) EP1448545B1 (https=)
JP (1) JP2005506334A (https=)
AT (1) ATE414697T1 (https=)
DE (1) DE60229975D1 (https=)
ES (1) ES2315430T3 (https=)
WO (1) WO2003029242A1 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003154D0 (en) * 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
CN101624391A (zh) * 2001-06-11 2010-01-13 病毒化学医药公司 用作黄病毒感染抗病毒剂的噻吩衍生物
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
TW200403991A (en) * 2002-04-11 2004-03-16 Smithkline Beecham Corp NF-κb inhibitors
AU2003249683A1 (en) * 2002-06-06 2003-12-22 Smithkline Beecham Corporation Nf-:b inhibitors
SE0202280D0 (sv) * 2002-07-19 2002-07-19 Astrazeneca Ab Novel compounds
SE0202279D0 (sv) * 2002-07-19 2002-07-19 Astrazeneca Ab Novel comppounds
JP2006512313A (ja) 2002-10-31 2006-04-13 アムジェン インコーポレイテッド 抗炎症剤
US20060116419A1 (en) * 2002-12-06 2006-06-01 Callahan James F Nf-kb inhibitors
US7402608B2 (en) * 2002-12-10 2008-07-22 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of Flavivirus infections
SE0300091D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300092D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
DE602004017478D1 (de) 2003-08-15 2008-12-11 Astrazeneca Ab Substituierte thiophene und deren verwendungen
US7119102B2 (en) * 2003-12-05 2006-10-10 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
BRPI0418351A (pt) * 2004-01-05 2007-05-08 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, métodos de limitar a proliferação celular em um humano ou animal, de tratamento de um humano ou animal sofrendo de cáncer, de tratamento de profilaxia de cáncer, de tratamento de um humano ou animal sofrendo de uma doença neoplásica, de tratamento de um humano ou animal sofrendo de uma doença prolifetativa de tratamento de cáncer, para o tratamento de infecções associadas com cáncer, para o tratamento profilático de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método de inibir a chk1 quinase, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo
GB0402809D0 (en) * 2004-02-09 2004-03-10 Glaxo Group Ltd Chemical compounds
AU2005233437A1 (en) * 2004-04-12 2005-10-27 Sankyo Company, Limited Thienopyridine derivatives
HRP20100678T1 (hr) 2005-03-29 2011-02-28 Icos Corporation Derivati heteroariluree korisni kao inhibitori chk1
BRPI0610283A2 (pt) * 2005-05-13 2010-10-19 Virochem Pharma Inc composto, uso do mesmo na preparação de um medicamento para o tratamento ou prevenção de uma infecção por vìrus de hepatite c, composição farmacêutica e combinação farmacêutica
EP1989203A2 (en) 2006-02-16 2008-11-12 Millennium Pharmaceuticals, Inc. Alpha carbolines and uses thereof
CA2670260A1 (en) 2006-11-15 2008-05-22 Virochem Pharma Inc. Thiophene analogues for the treatment or prevention of flavivirus infections
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
KR20130097813A (ko) 2008-04-21 2013-09-03 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
JP2010006717A (ja) * 2008-06-24 2010-01-14 Kyorin Pharmaceut Co Ltd ジヒドロチエノ［２，３−ｅ］インダゾール化合物
CN102171204B (zh) 2008-10-02 2014-08-20 旭化成制药株式会社 8位取代异喹啉衍生物及其用途
US20100136096A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100135983A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100135984A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100137247A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100137246A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100136094A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136095A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
WO2011077502A1 (ja) * 2009-12-21 2011-06-30 杏林製薬株式会社 ジヒドロチエノ［２，３－ｅ］インダゾール化合物
EP2520292A1 (en) 2011-05-06 2012-11-07 Helmholtz-Zentrum für Infektionsforschung GmbH Use of spirangiens for the treatment or prevention of IL-8 or IL-6 mediated disorders
US20150167097A1 (en) 2012-09-20 2015-06-18 Emory University CLASSIFIERS OF NF-kB PATHWAY ACTIVATION, DEVICES, AND METHODS OF USE THEREOF
JP7033789B2 (ja) 2016-06-29 2022-03-11 オトノミー，インク． トリグリセリド耳用製剤とその使用
EP3652542A1 (en) 2017-07-14 2020-05-20 Protea Biopharma N.V. Methods and means for diagnosing and/or treating a fatiguing illness
ES3011633T3 (en) 2017-08-31 2025-04-07 Ahammune Biosciences Private Ltd Thiophene compounds, process for synthesis and use thereof for the treatment of autoimmune disorders
CN115161289B (zh) * 2022-03-14 2023-12-05 东南大学 一种用于炎症性疾病治疗的重组腺相关病毒及其构建方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1468012A (en) * 1973-08-09 1977-03-23 Beecham Group Ltd 2-amino-3-carboxy-thiophene derivatives
DE4039734A1 (de) * 1990-12-13 1992-06-17 Basf Ag Substituierte 2-aminothiophene enthaltende herbizide mittel
US6274590B1 (en) * 1993-01-15 2001-08-14 G. D. Searle & Co. Method of treating skin related conditions
DE19642451A1 (de) * 1996-10-15 1998-04-16 Merck Patent Gmbh Aminothiophencarbonsäureamide
CN1332943C (zh) * 1998-07-08 2007-08-22 萨诺费－阿文蒂斯德国有限公司 硫取代的磺酰基氨基羧酸n－芳基酰胺,其制备方法、用途以及含有该化合物的药物制剂
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
US6414013B1 (en) * 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
EP1324759A4 (en) * 2000-10-12 2004-05-12 Smithkline Beecham Corp NF - G (K) B INHIBITORS
US6713638B2 (en) * 2001-05-18 2004-03-30 Joel M. Linden 2-amino-3-aroyl-4,5 alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors
CN101624391A (zh) * 2001-06-11 2010-01-13 病毒化学医药公司 用作黄病毒感染抗病毒剂的噻吩衍生物
SE0102617D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
US6835745B2 (en) * 2002-01-15 2004-12-28 Wyeth Phenyl substituted thiophenes as estrogenic agents
US7084178B2 (en) * 2003-11-26 2006-08-01 Bristol-Myers Squibb Company Antiamyloid phenylsulfonamides: N-cycloalkylcarboxamides derivatives

Similar Documents

Publication Publication Date Title
JP2005506334A5 (https=)
JP2006510676A5 (https=)
JP2019131569A5 (https=)
JP2019513804A5 (https=)
JP2004535466A5 (https=)
JP2007522142A5 (https=)
JP2006182786A5 (https=)
JP2008504363A5 (https=)
JP2017514839A5 (https=)
JP2018150331A5 (https=)
ES2407807T3 (es) Derivados de tiazolilo 2-amino-4,5-trisustituidos y su uso frente a enfermedades autoinmunitarias
JP2006514626A5 (https=)
JP2008543860A5 (https=)
CA2417148A1 (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
JP2012255002A5 (https=)
CA2556463C (en) Dihydropyridinone derivatives
JP2008512490A5 (https=)
JP2008501637A5 (https=)
AU2023226778B2 (en) Heteroarylamidopyridinol derivative and pharmaceutical composition comprising same as active ingredient for prevention or treatment of autoimmune disease
JP2005501012A5 (https=)
JP2005529155A5 (https=)
JP2018135343A5 (https=)
JP2005508955A5 (https=)
CA2628844A1 (en) Pyrazole derivatives and their medical use
JP2005500370A5 (https=)